At F2G, we understand that the fight against fungal diseases requires more than just treatment innovation, it demands a comprehensive approach that considers the connection between human, animal, and environmental health. The "One Health" approach highlights the reality that fungal infections often stem from interactions within our ecosystems. By recognizing these links, we can better address the root causes of fungal diseases and advance more effective, sustainable treatments. This #FungalWeek24, learn more from the Centers for Disease Control and Prevention about how fungal diseases are a One Health issue: https://bit.ly/3Z2lxNJ
F2G
Biotechnology Research
Manchester, England 6,655 followers
The rare fungal disease company
About us
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This differentiates the orotomides from the currently marketed antifungal agents. Olorofim (formerly F901318) is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective. Olorofim is in a Phase 2b open-label study focusing on rare and resistant invasive fungal infections including invasive aspergillosis (including azole-resistant strains), coccidioidomycosis and scedosporiosis (including lomentosporiosis). Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA. F2G is headquartered in the UK with subsidiaries in the US and Austria.
- Website
-
http://www.f2g.com
External link for F2G
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Manchester, England
- Type
- Privately Held
Locations
-
Primary
Get directions
Lankro Way, Eccles
Manchester, England M30 0LX, GB
-
Get directions
Seilerstätte 17
13
Vienna, 1010, AT
-
Get directions
116 Village Blvd
200
Princeton, New Jersey 08540, US
Employees at F2G
Updates
-
Fungal diseases and antimicrobial resistance are on the rise globally, yet there has been limited treatment innovation to address these pressing challenges. This #FungalWeek24, join us in raising awareness and education on these critical issues in the space. Learn more from the Centers for Disease Control and Prevention: https://bit.ly/3Z2lxNJ
-
-
We are thrilled to announce the close of a $100 million financing round, led by new investor AMR Action Fund with strong participation from new investor Intermediate Capital Group (ICG) Life Sciences and existing investors. The funds will be used to advance the late-stage development and commercialization of our novel antifungal drug candidate in the US. Read our new press with financing details on the media section of the F2G corporate website: https://bit.ly/3UlKDVE
-
At #SXSW2024, our Chief Medical Officer, Dr. John Rex, joined a panel of infectious disease experts from government and academia to discuss the increasing threat of fungal infections, the effects of climate change, and addressing the global challenge. Read more in the Washington Examiner: https://bit.ly/3IyyuWd #FungiForumSXSW SXSW
-
We are proud to sponsor the 68th Annual Coccidioidomycosis Study Group because we believe in the power of knowledge exchange to drive innovation in the prevention and treatment of invasive fungal infections like Coccidioidomycosis (valley fever). We’ll share data through two oral presentations and a poster highlighting the progress being made by our team and partners. To learn more about what we are doing to address valley fever, visit: https://bit.ly/3THVE1h
-
-
Attending #SXSW2024? Our Chief Medical Officer, Dr. John Rex, will join a dynamic panel of fungal disease experts on Monday, March 11 at 4pm CST in Austin, TX. Don’t miss out on this engaging discussion—add it to your calendar now! https://brnw.ch/21wHHVN @sxsw #FungiForumSXSW
-
Attending #SXSW2024? Our Chief Medical Officer, Dr. John Rex, will join a dynamic panel of fungal disease experts on Monday, March 11 at 4pm CST in Austin, TX. Don’t miss out on this engaging discussion—add it to your calendar now! https://brnw.ch/21wHHsP @sxsw #FungiForumSXSW
-
Join us at #SXSW2024 on Monday, March 11 at 4pm CST, where a panel of infectious disease experts from F2G, government, and academia will explore challenges posed by fungi, treatment complexities, cross-resistance, and shared DNA hurdles in antifungal development. Learn more: https://brnw.ch/21wHF4y #FungiForumSXSW
-
-
At F2G, we’re united by the belief that patients fighting rare life-threatening fungal infections need more options. Learn how we are harnessing the power of a novel science to advance an antifungal by visiting our new website: https://brnw.ch/21wGLdK
-
-
F2G reposted this
We’re thrilled to announce the launch of the new F2G website. It tells our story of tenacity as we grow and navigate complex challenges to deliver a novel antifungal so that patients can have a fighting chance. Explore our new website by clicking here: https://brnw.ch/21wGymL
-